| Ellen Cynthia Barton, DPM | |
|
323 S 18th Ave, Sturgeon Bay, WI 54235-1401 | |
| (920) 746-0510 | |
| Not Available |
| Full Name | Ellen Cynthia Barton |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 6 Years |
| Location | 323 S 18th Ave, Sturgeon Bay, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699263996 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 1173 (Wisconsin) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Door County Medical Center | Sturgeon bay, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Door County Memorial Hospital | 5395735088 | 66 |
News Archive
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Doctors' quest to see what is happening inside a living body has been hampered by the limits on detecting tiny components of internal structures and events.
› Verified 4 days ago
| Provider Name | Gundersen Clinic Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Doctors' quest to see what is happening inside a living body has been hampered by the limits on detecting tiny components of internal structures and events.
› Verified 4 days ago
| Provider Name | Door County Memorial Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093743874 PECOS PAC ID: 5395735088 Enrollment ID: O20040514000588 |
News Archive
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Doctors' quest to see what is happening inside a living body has been hampered by the limits on detecting tiny components of internal structures and events.
› Verified 4 days ago
| Provider Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Doctors' quest to see what is happening inside a living body has been hampered by the limits on detecting tiny components of internal structures and events.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ellen Cynthia Barton, DPM 323 S 18th Ave, Sturgeon Bay, WI 54235-1401 Ph: (920) 746-0510 | Ellen Cynthia Barton, DPM 323 S 18th Ave, Sturgeon Bay, WI 54235-1401 Ph: (920) 746-0510 |
News Archive
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.
Doctors' quest to see what is happening inside a living body has been hampered by the limits on detecting tiny components of internal structures and events.
› Verified 4 days ago
Peninsula Podiatry Llc Podiatrist Medicare: Medicare Enrolled Practice Location: Bldg 4 2, 30 North 18th Avenue, Sturgeon Bay, WI 54235 Phone: 920-743-6668 Fax: 920-743-9222 | |
Dr. Bradley Gerard Burkart, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: Bldg 4 2, 30 North 18th Avenue, Sturgeon Bay, WI 54235 Phone: 920-743-6668 |